Help us to engage the forces!

CMS President Dr. Thomas M. Anderson addresses the Council, describing the Society’s recent advocacy initiatives on physicians’ behalf. He’s flanked by (from left): Dr. Kenneth G. Busch, secretary; Ted Kaneklakes, CMS executive director; Dr. Howard Axe, president-elect; and Dr. Robert W. Panton, chairman of the Council. Coverage begins on page 2.

On the national scene the U.S. Supreme Court has agreed to decide whether and in what form the Court will consider the constitutional issues raised by the Patient Protection and Affordable Care Act, or at least possibly address the riveting problem of the individual mandate to purchase health insurance.

At the local level, the Chicago Medical Society continues to sponsor the educational activities that members have told us they need. Our well-attended programs addressed the OSHA requirements for bloodborne pathogens, patient safety, health information technology, and financial incentives for demonstrating “meaningful use.” Physicians and office managers who attended our programs scored them as highly informative. More are being planned to assist you through the bewilderingly complex changes in medical practice. Keep in touch with us at www.cmsdocs.org or ASKCMSDOCS.ORG and plan to attend!

On the state level, your membership linked to ISMS provides funding for critical activities like watching and nudging our legislators in Springfield, otherwise known as lobbying on your behalf.

The good news is that the Illinois Medical Practice Act has been renewed. That document prevents unlicensed individuals with little or no education or training from legally engaging in the

(continues on page 2)
practice of medicine. Better yet, legislators rejected the Illinois Department of Financial and Professional Regulation’s proposal to double the current medical licensure renewal fee and reduce the renewal cycle to two years or less. We fought hard on your behalf to achieve these victories.

The bad news is that legislators renewed the Act for only one year, and we expect the demand for a fee increase to resurface next year.

We need your support in this ongoing battle so we can continue to engage the forces that would diminish your ability to treat patients.

You can help by renewing your membership, recruiting your colleagues as new members, and donating to the ISMS PAC. It is an unfortunate fact of political life in Illinois that legislators are too often tone deaf unless the musical quality of the argument is amplified by financial contributions.

Thomas M. Anderson, MD
President,
Chicago Medical Society
As a physician with a part-time practice schedule, I need a medical liability insurer that understands my specific needs. ISMIE Mutual Insurance Company was founded and remains owned and managed by physician policyholders. They understand what physicians need because they are physicians. From part-time coverage to suspended coverage, ISMIE Mutual is dedicated to meeting the needs of physicians as our careers change. I am ISMIE.

ISMIE Mutual offers the support and protection you want from a medical liability insurance company. We are the Physician-First Service Insurer® in everything we do. From underwriting to risk management to claims, we put you first.

Depend on ISMIE for your medical liability protection – so you can focus on the reason you became a physician: to provide the best patient care possible.

Not an ISMIE Mutual policyholder and interested in obtaining a comparison quote for your medical liability coverage? Contact our Underwriting Division at 800-782-4767, ext. 3350, or e-mail us at underwriting@ismie.com. Visit our web site at www.ismie.com.
What you should know about electronic health records

By Abel Kho MD, MS
Co-executive Director,
Chicago Health IT Regional Extension Center

The American Recovery and Reinvestment Act (ARRA) of 2009 created an unprecedented federal incentive for physicians to adopt electronic health records (EHRs). The “meaningful use” regulations provide guidance on how to best use an EHR to improve the quality and safety of the care physicians provide to their patients.

Here are 10 practical points physicians should understand:

- EHRs are here to stay – Newly minted physicians trained with them, and expect them as part of their routine practice. Nationwide, EHR adoption rates are approaching 50%.
- Physicians who care for Medicare or Medicaid patients likely qualify for EHR incentive payments of up to or $44,000 (Medicare), or $63,750 dollars (Medicaid). After 2012, Medicare payments decrease yearly, so early is better!
- Physicians who qualify for the Medicaid incentive should pursue this option because it offers more flexibility and funding. The state of Illinois should start dispensing Medicaid EHR incentive payments early next year and registration is already open: www.cms.gov/EHRIncentivePrograms/
  - Meaningful use is achievable. Many EHRs are designed around these specifications to make it easier for physicians to document appropriately.
  - Meaningful use requires use of a certified EHR. Most EHRs are certified but for a complete list go to: http://onc-chpl.force.com/ehrcert
  - There is not one right EHR solution. How a physician implements an EHR is at least as important as his or her choice of EHR.
  - Stark Law relaxation allows not-for-profit hospitals to offset up to 85% of the cost of implementing an EHR for affiliated physicians. Physicians should check with their local hospitals to see if they offer such a program.
  - Making the first step and deciding to use an EHR is the hardest. Once one decides, there are local resources to help. The Regional Extension Center (REC) program is the federally funded local resource to help physicians achieve meaningful use of EHRs. Regional extension centers are NOT vendors, but are funded by the same legislation that created the EHR incentive payments.
  - The REC for Chicago is the Chicago Health IT Regional Extension Center (www.chitrec.org). The rest of the state of Illinois is covered by the Illinois Health IT Regional Extension Center or IL-HITREC (www.ilhitrec.org).
  - What are the most common problems related to achieving meaningful use? Privacy and security assessments, public health reporting, and quality measurement. The RECs have experience navigating these sticking points.
  - Physicians will likely never have another opportunity to receive federal funds that help pay for implementing an EHR. But the window is narrow; by 2015 the Medicare EHR incentive will be replaced with penalties.

CHITREC can help you!

CHITREC offers free staff assistance as well as reimbursement for expenses incurred towards achieving “meaningful use.” But federally funded slots are limited. Physicians are encouraged to contact CHITREC soon at http://chitrec.org/about/contact to see if they qualify.

(continues on page 6)
Kindred Healthcare understands that when people are discharged from a traditional hospital, they often need continued care in order to recover completely. That's where we come in.

Kindred offers services including aggressive, medically complex care, intensive care, short-term rehabilitation and compassionate long-term care for dementia or Alzheimer's.

Doctors, case managers, social workers and family members don’t stop caring simply because their loved one or patient has changed location.

Neither do we.

Come see how we care at www.continuethecare.com.

Dedicated to Hope, Healing and Recovery

CONTINUE THE CARE

LONG-TERM ACUTE CARE HOSPITALS • NURSING AND REHABILITATION CENTERS • TRANSITIONAL AND SUBACUTE CARE • ASSISTED LIVING CONTRACT THERAPY SERVICES • HOME CARE • HOSPICE
For the public, the big news in health these days is health reform and health care costs. But for many physicians in the front lines, the real story is electronic health records (EHRs). The idea of EHRs evokes many questions for physicians, including, “Are they really necessary?” “Which vendor should be used?” “How can we fund EHRs?” “How will we learn to use them?” Financial incentives (or are they mandates?) from the federal government offer some promise for recouping the costs of implementation, but the questions, “What exactly is ‘meaningful use,’ and ‘will we ever really receive any money anyway?’” still exist. These are legitimate questions for which medical professional societies, the federally funded Regional Extension Centers (CHITREC) and perhaps health systems are doing their best to provide answers.

Meanwhile, let’s start with some basics that should provide concrete and understandable information that can make the path to the implementation of EHRs seem less arduous with the end result being worth the work.

**Learning to adapt to electronic health records: residency redux or pathway to improved effectiveness?**

By Margaret Gadon, MD, MPH, Clinical Director, Telligen

Why is there such a push to move to EHRs from paper records?

There are a multitude of reasons, including improved quality of care and patient safety, improved coordination of care and ease of patient/physician communication.

Providers who have implemented EHRs have derived much value from them. They have experienced improved communication between primary care and specialist physicians and hospitalists and reductions in preventable medical errors. Also, they’ve seen an increasing number of patient transitions between sites of care and clinicians with the insertion of the hospitalist in many health care systems: these transitions are now impacting patient safety. The current health care system is complex and patients make a journey through this system as they receive their care. As physicians, we are part of a team and share in the responsibility for coordinating this care and ensuring, as much as possible, the safety and well being of those for whom we care. The EHR records this journey; it is our ally in preserving trust and developing strong relationships with our patients.

(continues on page 8)
Tame the beast.

Running a practice is getting more complicated — and frustrating. And in your gut, you know traditional software won’t make it simpler. Join the 27,000 providers who use our cloud-based practice management, EHR, and patient communications services to tame the beast.

Put the power of the cloud to work. 800.981.5085 : athenahealth.com/ChicagoMed
Why does it take so much more time and work to use electronic health records?

Like anything that's new to us, implementing an EHR certainly can seem time-consuming at the onset. However, the learning period depends on an individual’s comfort level with computers and understanding and acceptance of the requisite changes in practice mandated by an EHR. If we use an EHR simply to type our notes and make no other changes, the EHR is likely to continue to take more time than paper charts. But, if we change the way the office is set up, the way patients move through the office, and the tasks of each staff member, we may be able to see patients more efficiently.

For example, another clinician can document the use of medications and screening tests or immunizations done outside the office and ensure that all data from a referral site is available when the physician enters the exam room. This way, providers can engage patients more easily by jointly viewing their information on the screen, in graphic form with average value comparisons to similar patients. This has been shown to help with treatment adherence and improved outcomes. Such practices also lead to improved physician performance. And with the trend toward increased payment for quality care, the EHR aligns directly with higher physician reimbursement.

What is meaningful use, what is the goal and what do I have to do to achieve this?

The simple answer to this question is that meaningful use is a strategy for encouraging hospitals and clinicians to use a standard set of processes that will allow for the creation of population health databases and health information sharing between sites of care. Managing a population’s health begins at the practice level. By identifying communities and populations in need, EHRs give us the opportunity to make changes at the system or practice level to improve outcomes. At the state or federal level, health information technology ensures that public funds for health and health care funding are more effectively targeted to populations in need.

There is no doubt that for many physicians who have been in practice for more than 15 years, the transition to EHRs is an unwelcome challenge. Many physicians long for days when the pace of medicine was slower, patients stayed with their physicians for years, and patients were cared for in-hospital as well as in the office. With our technologically sophisticated imaging and communications, electronic recording and sharing of health information is the smart way to proceed. So, yes, it is a steep hill to climb; but the end result—for physicians and patients—is worth the trip.

Dr. Gadon is clinical director of Telligen and adjunct assistant professor in the Department of Medicine at the Feinberg School of Medicine, Northwestern University.

Telligen is a corporation that applies information to health care quality improvement and care management. It contracts with Medicare to provide services for the Illinois Quality Improvement Association.

---

Paid Up & Paid Off!

Stamp out unpaid bills!

The Chicago Medical Society has partnered with I.C. System to provide members with individualized accounts receivable solutions.

I. C. System, Inc.
P.O. Box 64137
St. Paul, MN  55164-0137
www.icsystem.com

Call Today!
1-800-279-3511

---

Chicago Medicine, No. 7, 2011
Page 8
SAVOR

your arrival.

One to three bedrooms & penthouses from $1.4 million in the heart of Chicago’s Magnificent Mile.

Please call to schedule a private showing: 312-242-5980

Visit us online: TheResidencesChicago.com

Delivery begins early 2012

A Prism Development

Exclusively marketed by Prudential Rubeloff
TO ENCOURAGE FASTER ADOPTION OF EHRS, the U.S. Department of Health and Human Services delayed the Stage 2 requirements for Medicare and Medicaid EHR Meaningful Use Incentive Programs until 2014.

Under the previous requirement, physicians who began participating in the Medicare EHR incentive program in 2011 would have to meet new standards in 2013, according to the Nov. 30 HHS announcement. If they began participation in 2012, they could wait until 2014 to meet these new standards and still qualify for the same incentive payment.

Physicians and hospitals who adopted the Stage 1 standards in 2011 may qualify for incentive payments in 2011 and 2012. (Eligible physicians may receive as much as $44,000 under the Medicare incentive program, and $63,750 under the Medicaid program.)

While expressing support for the delay, the AMA encouraged HHS to continue evaluating Stage 1 and work on increasing the number of physicians participating in the programs before finalizing requirements for Stage 2.

A CDC survey found that 52% of office-based physicians in the U.S. plan to take advantage of the incentive payments available through Medicare and Medicaid EHR Incentive Programs.

The CDC data also show the percentage of physicians who have adopted basic EHRs in their practice has doubled from 17 to 34% between 2008 and 2011 (with the percent of primary care doctors using this technology nearly doubling from 20 to 39%).

As physicians, we have so many unknowns coming our way...

One thing I am certain about is my malpractice protection.

As physicians, we have so many unknowns coming our way...
Why choose between national resources and local clout?

In Illinois, The Doctors Company protects its members with both.

With nearly 55,000 member physicians, we are the nation’s largest insurer of physician and surgeon medical liability. We constantly monitor emerging trends and quickly respond with innovative solutions, like incorporating coverage for privacy breach and Medicare reviews into our core medical liability coverage.

Because we are the second-largest carrier in Illinois, our members also benefit from significant local clout—including our long-standing relationships with the state’s leading attorneys and expert witnesses, plus litigation training tailored to the Illinois legal environment.

This uncompromising support of doctors has earned recognition from many prestigious medical organizations at national and local levels, including the American College of Physicians, American College of Surgeons, American Society of Plastic Surgeons®, American Association of Neurological Surgeons, American Academy of Otolaryngology—Head and Neck Surgery, and the Society of Hospital Medicine.

To learn more about our benefits for Illinois members—including the Tribute® Plan, an unrivaled financial career reward—contact our Chicago office at (800) 748-0465 or visit www.thedoctors.com.

We relentlessly defend, protect, and reward the practice of good medicine.
**Medicare e-prescribing payment**

STARTING WITH THE NEW YEAR, PAYMENT reductions set in for eligible physicians who have not become “successful” electronic prescribers in Medicare’s eRx Incentive Program and have not applied for the hardship exemption. The 1% payment reduction is for Part B-covered professional services.

Eligible doctors and practices will see further reductions in 2013 (98.5%) and 2014 (2%) if they have not met the electronic prescribing requirement.

For additional information, please visit [http://www.cms.gov/erxincentive](http://www.cms.gov/erxincentive)

**Revised ABN form**

The revised Advanced Beneficiary Notice (ABN) of Non-coverage goes into effect Jan. 1, 2012. The ABN, which is required whenever Medicare is expected to deny payment, is available for immediate use and can be accessed via the link below. Medicare will consider the old forms invalid.

For more information, and details on mandatory and voluntary use, go to [http://www.cms.gov](http://www.cms.gov)

**HIPAA 5010 standards compliance**

Enforcement of the updated HIPAA 5010 electronic transmission standards begins March 31, 2012, according to the Centers for Medicare & Medicaid Services (CMS).

The Jan. 1 compliance date remains in effect, however.

Nonetheless, the federal agency encourages physicians to continue their version 5010 implementation programs as planned.

CMS announced the delay in enforcement after determining that some covered entities and their trading partners will not be compliant by Jan. 1. Many are still awaiting software upgrades, according to CMS.

The following organizations offer resources to help with the 5010 transition and future ICD-10 adoption.

- Centers for Medicare and Medicaid Services
- Electronic Billing & EDI Transactions
- Illinois Department of Healthcare and Family Services
  - Companion Guide Updates for HIPAA 5010 - Transactions
- CDC’s National Center for Health Statistics
  - ICD-10-CM Guidelines, List of Codes & Descriptions, and General Equivalency Mappings

**Insurance coding exchange to benefit members**

AT MEMBERS’ BEHEST, CMS IS BUILDING A service to help the medical team avoid coding pitfalls that can end up costing time and money.

With the redesign of the Society’s website, members can soon access a password-protected coding exchange to share their coding experiences and suggestions. A medical billing company will answer specific questions about the utilization and interpretation of various medical codes.

Featuring a forum area and blog for posting coding updates, the new section will help small groups and solo practices that lack the resources to implement coding costly updates. CMS will routinely circulate or email blast updates by specialty as they become available.

According to members who advocated for this benefit, medical coding is increasingly complex and each insurance company interprets codes differently. Mistakes can lead to audits and fines, along with demands for recoupment. Insurance companies have stepped up their audits and penalties on physicians.
Choice

Select the plan, coverage options and deductibles that meet your needs and budget.

Individual and Group Health Insurance Plans

When it comes to your health insurance, you deserve the best combination of freedom, choice and price. Enjoy the freedom to see the doctor, specialist and hospital of your choice without referrals. Designed by physicians for physicians: call now for your personal consultation and competitive rate quote.

ISMS/CMS Members
1-800-621-0748 • www.pbtinsurance.com

ISDS Members
1-866-898-0926 • www.isdsinsurance.com

Sponsored by: PBTLC is a wholly owned subsidiary of:

Administered by Affinity Insurance Services, Inc.
CMS MEMBERS ARE ENCOURAGED TO CALL ISMS’ Division of Member Advocacy when dealing with confusing policies or procedures set up by third-party payers.

The service helps iron out problems with government agencies (Medicaid and Medicare), private insurers, HMOs, PPOs, IPAs, etc.

Physicians will need to complete the ISMS Hassle Factor Log to facilitate the tracking, monitoring and resolving of issues presented. Data provided may be shared with specific payers, state agencies or internal ISMS councils in order to address, track, and resolve problems. Upon submission of this data, ISMS advocacy staff will contact the physician to discuss his or her concern.

CMS/ISMS members can also request to have an ISMS Hassle Factor Log sent to them via fax or mail.

For information, please contact the ISMS Division of Member Advocacy (800) 782-ISMS; or e-mail: advocacy@isms.org.

---

**ISMS offers help for payer hassles**

**Postal Statement of Ownership**

![Postal Statement of Ownership Image](image-url)
DULERA is indicated for the treatment of asthma in patients ≥12 years of age.

Discover the powerful efficacy of DULERA

DULERA is NOT indicated for the relief of acute bronchospasm.

Visit discoverdulera.com to learn more.

Selected Important Safety Information about DULERA

WARNING: ASTHMA-RELATED DEATH
Long-acting beta-2-adrenergic agonists (LABA), such as formoterol, one of the active ingredients in DULERA, increase the risk of asthma-related death. Data from a large placebo-controlled U.S. study that compared the safety of another LABA (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of the LABA, including formoterol. Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA. Available data from controlled clinical trials suggest that LABA increase the risk of asthma-related hospitalization in pediatric and adolescent patients.

When treating patients with asthma, prescribe DULERA only for patients with asthma not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid, or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and LABA. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue DULERA) if possible without loss of asthma control, and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid. Do not use DULERA for patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids.

Before prescribing DULERA, please read the Brief Summary of Prescribing Information, including Boxed Warning about asthma-related death, on following pages.

For additional copies of the Prescribing Information, call 1-800-672-6372, visit dulera.com, or contact your Merck representative.
A 28-week, placebo-controlled US study comparing the safety of salmeterol with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in patients receiving salmeterol (13/13,176 in patients treated with salmeterol) vs. 3/13,179 in patients treated with placebo; RR 4.37, 95% CI 1.25, 15.4 (p=0.01). This finding with salmeterol is considered a class effect of the LABAs, including formoterol, one of the active ingredients in DULERA. No study adequate to determine whether the rate of asthma-related death is increased with DULERA has been conducted.

Clinical studies with formoterol suggested a higher incidence of serious asthma exacerbations in patients who received formoterol fumarate than in those who received placebo. The sizes of these studies were not adequate to precisely quantify the differences in serious asthma exacerbation rates between treatment groups.

5.2 Deterioration of Disease and Acute Episodes
DULERA should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma. DULERA is not indicated for patients with acutely deteriorating asthma. The initiation of DULERA in this setting is not appropriate.

Increasing use of inhaled, short-acting beta-2-agonists is a marker of deteriorating asthma. In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of DULERA with a higher strength, adding additional inhaled corticosteroids, or initiating systemic corticosteroids. Patients should not use more than 2 inhalations twice daily (morning and evening) of DULERA. DULERA is not indicated for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. An inhaled, short-acting beta-2-agonist, not DULERA, should be used to relieve acute symptoms such as shortness of breath. When prescribing DULERA, the physician must also provide the patient with an inhaled, short-acting beta-2-agonist (e.g., albuterol) for treatment of acute symptoms, despite regular twice-daily (morning and evening) use of DULERA.

When beginning treatment with DULERA, patients who have been taking oral or inhaled, short-acting beta-2-agonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs.

5.3 Excessive Use of DULERA and Use with Other Long-Acting Beta-2-Agonists
As with other inhaled drugs containing beta-2-agonist agents, DULERA should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medications containing long-acting beta-2-agonists, as an overdose may result. Clinically significant cardiovascular effects, including fatalities, have been reported in association with excessive use of inhaled sympathomimetic drugs. Patients using DULERA should not use an additional long-acting beta-2-agonist (e.g., salmeterol, formoterol fumarate, arformoterol tartrate) for any reason, including prevention of exercise-induced bronchospasm (EIB) or the treatment of asthma.

5.4 Local Effects
In clinical trials, the development of localized infections of the mouth and pharynx with Candida albicans have occurred in patients treated with DULERA. If oropharyngeal candidiasis develops, it should be treated with appropriate local or systemic (i.e., oral antifungal therapy while remaining on treatment with DULERA therapy, but at times therapy with DULERA may need to be interrupted. Advise patients to rinse the mouth after inhalation of DULERA.

5.5 Immunosuppression
Persons who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals.

Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids. In such children or adults who have not had these diseases or who are not properly immunized, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affect the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IM) may be indicated. See the respective package inserts for complete VZIG and IM prescribing information. If chickenpox develops while treatment with antibacterial agents may be considered.

DULERA should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract, untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.

5.6 Transferring Patients from Systemic Corticosteroid Therapy
Particular care is needed for patients who are transferred from systemically active corticosteroids to DULERA because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. After withdrawal from systemic corticosteroids, a number of months are required for recovery of hypothalamic-pituitary-adrenal (HPA) function.

Patients who have been previously maintained on 20 mg or more per day of prednisone (or its equivalent) may be most susceptible, particularly when their systemic corticosteroids have been almost completely withdrawn. During this period of HPA suppression, patients may exhibit signs and symptoms of adrenal insufficiency when exposed to stress (e.g., surgery, trauma, infection, particularly gastrointestinal) or other conditions associated with severe electrolyte loss. Although DULERA may improve control of asthma symptoms during these episodes, in
recommended doses it supplies less than normal physiological amounts of corticosteroids systemically and does NOT provide the mineralocorticoid activity needed to prevent these emergencies.

During periods of stress or severe asthma attack, patients who have been withdrawn from systemic corticosteroids should be instructed to resume oral corticosteroids (in large doses) immediately and to contact their physicians for further instruction. These patients should also be instructed to carry a medical identification card indicating that they may need supplementary systemic corticosteroids. Patients should be informed that signs and symptoms of adrenal insufficiency such as fatigue, tachycardia, weakness, nausea and vomiting, and hypotension.

Transfer of patients from systemic corticosteroid therapy to DULERA may unmask allergic conditions previously suppressed by the systemic corticosteroid therapy, e.g., rhinitis, conjunctivitis, eczema, arthritis, and eosinophilic conditions.

During withdrawal from oral corticosteroids, some patients may experience symptoms of systemically active corticosteroid withdrawal, e.g., joint and/or muscular pain, lassitude, and depression, despite maintenance or even improvement of respiratory function.

5.7 Corticosteroid and Adrenal Suppression

Mometasone furoate, a component of DULERA, will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. Since mometasone furoate is absorbed into the circulation and can be systemically active at higher doses, the beneficial effects of DULERA in minimizing HPA dysfunction may be expected only when recommended dosages are not exceeded and individual patients are titrated to the lowest effective dose.

Because of the possibility of systemic absorption of inhaled corticosteroids, patients treated with DULERA should be observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients postoperatively or during periods of stress for evidence of inadequate adrenal response.

It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients, particularly when mometasone furoate is administered at higher than recommended doses over prolonged periods of time. If such effects occur, the dosage of DULERA should be reduced slowly, consistent with accepted procedures for reducing systemic corticosteroids and for management of asthma symptoms.

5.8 Drug Interactions with Strong Cytochrome P450 3A4 Inhibitors

Caution should be exercised when considering the coadministration of DULERA with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, darilarnavir, indinavir, laronconazole, nefilatin, saquinavir, or telithromycin) because adverse effects related to increased systemic exposure to mometasone furoate may occur [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].

5.9 Paradoxical Bronchospasm and Upper Airway Symptoms

DULERA may produce inhalation induced bronchospasm with an immediate increase in wheezing after dosing that may be life-threatening. If inhalation induced bronchospasm occurs, it should be treated immediately with an inhaled, short-acting inhaled bronchodilator; DULERA should be discontinued immediately and alternative therapy instituted.

5.10 Immediate Hypersensitivity Reactions

Immediate hypersensitivity reactions may occur after administration of DULERA, as demonstrated by cases of urticaria, flushing, allergic dermatitis, and bronchospasm.

5.11 Cardiovascular and Central Nervous System Effects

Excessive beta-adrenergic stimulation has been associated with seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/m, arrhythmias, nervousness, headache, tremor, palpitation, nausea, dizziness, fatigue, malaise, and insomnia. Therefore, DULERA should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

Formoterol fumarate, a component of DULERA, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of DULERA at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce ECG changes, such as flattening of the T wave, prolongation of the QT interval, and ST segment depression. The clinical significance of these findings is unknown. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.

5.12 Reduction in Bone Mineral Density

Decreases in bone mineral density (BMD) have been observed with long-term administration of products containing inhaled corticosteroids, including mometasone furoate, one of the components of DULERA. The clinical significance of small changes in BMD with regard to long-term outcomes, such as fracture, is unknown. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care.

In a 2-year double-blind trial in 103 male and female asthma patients 18 to 50 years of age previously maintained on bronchodilator therapy (Baseline FEV1 85%–88% predicted), treatment with mometasone furoate dry powder inhaler 200 mcg twice daily resulted in significant reductions in lumbar spine (LS) BMD at the end of the treatment period compared to placebo. The mean change from Baseline to Endpoint in the lumbar spine BMD was -0.016 (-1.43%) for the mometasone furoate group compared to 0.002 (0.2%) for the placebo group. In another 2-year double-blind study in 87 male and female asthma patients 18 to 50 years of age previously maintained on bronchodilator therapy (Baseline FEV1 82%–83% predicted), treatment with mometasone furoate 400 mcg twice daily demonstrated no statistically significant changes in lumbar spine BMD at the end of the treatment period compared to placebo. The mean change from Baseline to Endpoint in the lumbar spine BMD was -0.018 (-1.57%) for the mometasone furoate group compared to -0.006 (0.43%) for the placebo group.

5.13 Effect on Growth

Orally inhaled corticosteroids, including DULERA, may cause a reduction in growth velocity in children who are treated with pediatric doses. Monitor the growth of pediatric patients receiving DULERA routinely (e.g., via stadiometry). To minimize the systemic effects of orally inhaled corticosteroids, including DULERA, titrate each patient’s dose to the lowest dosage that effectively controls his/her symptoms [see Use in Specific Populations (8.4)].

5.14 Glaucoma and Cataracts

Glaucoma, increased intraocular pressure, and cataracts have been reported following the use of long-term administration of inhaled corticosteroids, including mometasone furoate, a component of DULERA. Therefore, close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts [see Adverse Reactions (6)].

5.15 Coexisting Conditions

DULERA, like other medications containing sympathomimetic amines, should be used with caution in patients with convulsive disorders or thyrotoxicosis and in patients who are unusually responsive to sympathomimetic amines. Doses of DULERA when administered intranasally have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.

5.16 Hypokalemia and Hyperglycemia

Beta-agonist medications may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation. Clinically significant changes in blood glucose and/or serum potassium were seen infrequently during clinical studies with DULERA at recommended doses.

6 ADVERSE REACTIONS

Long-acting beta2-adrenergic agonists, such as formoterol, one of the active ingredients in DULERA, increase the risk of asthma-related death. Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA. Available data from controlled clinical trials suggest that LABA increase the risk of asthma-related hospitalization in pediatric and adolescent patients. Data from a large placebo-controlled US trial that compared the safety of another long-acting beta, adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol [see Warnings and Precautions (5.1)]. Systemic and local corticosteroid use may result in the following:

- Candidate albinism infections [see Warnings and Precautions (5.4)]
- Immunosuppression [see Warnings and Precautions (5.5)]
- Hypercorticism and adrenal suppression [see Warnings and Precautions (5.7)]
- Growth effects in pediatrics [see Warnings and Precautions (5.13)]
- Glaucoma and cataracts [see Warnings and Precautions (5.14)]

Because clinical trials are conducted under well-controlled conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

6.1 Clinical Trials Experience

The safety data described below is based on 3 clinical trials which randomized 1913 patients 12 years of age and older with asthma, including 679 patients exposed to DULERA for 12 to 26 weeks and 271 patients exposed for 1 year. DULERA was studied in two placebo- and active-controlled trials (n=781 and n=782, respectively) and in a long-term 52-week safety trial (n=404). In the 12- to 26-week clinical trials, the population was 12 to 84 years of age, 41% male, 50% female, 73% Caucasians, 27% non-Caucasians. Patients received two inhalations twice daily of DULERA (100 mcg/5 mcg or 200 mcg/5 mcg), mometasone furoate MDI (100 mcg or 200 mcg), formoterol MDI (5 mcg) or placebo. In the long term 52-week active-comparator safety trial, the population was 12 years to 75 years of age with asthma, 37% male and 63% female, 47% Caucasians, 53% non-Caucasians, each receiving two inhalations twice daily of DULERA 100 mcg/5 mcg or 200 mcg/5 mcg, or an active comparator. The incidence of treatment emergent adverse reactions associated with DULERA in Table 2 below is based upon pooled data from 2 clinical trials 12 to 26-week in duration in patients 12 years and older treated with two inhalations twice daily of DULERA (100 mcg/5 mcg or 200 mcg/5 mcg), mometasone furoate MDI (100 mcg or 200 mcg), formoterol MDI (5 mcg) or placebo.
Oral candidiasis has been reported in clinical trials at an incidence of 0.7% in patients using DULERA 100 mcg/s mcg, 0.8% in patients using DULERA 200 mcg/s mcg and 0.5% in the placebo group.

Long Term Clinical Trial Experience
In a long-term safety trial in patients 12 years and older treated for 52 weeks with DULERA 100 mcg/s mcg (n=141), DULERA 200 mcg/s mcg (n=130) or an active comparator (n=133), safety outcomes in general were similar to those observed in the shorter 12 to 26 week controlled trials. No asthma-related deaths were observed. Dysphonia was observed at a higher frequency in the longer term treatment comparison (2.6%) than in the short-term trials (1.5%) for patients receiving DULERA 100 mcg/s mcg and S1/3(3.8%) patients receiving DULERA 200 mcg/s mcg. No clinically significant changes in blood chemistry, hematology, or ECG were observed.

7 DRUG INTERACTIONS
In clinical trials, concurrent administration of DULERA and other drugs, such as short-acting beta-agonist and intranasal corticosteroids have not resulted in an increased frequency of adverse drug reactions. No formal drug interaction studies have been performed with DULERA. The drug interactions of the combination are expected to reflect those of the individual components.

7.1 Inhibitors of Cytochrome P450 3A4
The main route of metabolism of corticosteroids, including montelukast furoate, a component of DULERA, is via cytochrome P450 3A4 (CYP3A4). After oral administration of ketoconazole, a strong inhibitor of CYP3A4, the mean plasma concentration of orally inhaled montelukast furoate increased. Concomitant administration of CYP3A4 inhibitors may inhibit the metabolism of, and increase the systemic exposure to, montelukast furoate. Caution should be exercised when considering coadministration of DULERA with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see Warnings and Precautions (5.8) and Clinical Pharmacology (12.3)].

7.2 Adrenergic agents
If additional adrenergic drugs are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of formoterol, a component of DULERA, may be potentiated.

7.3 Xanthine derivatives
Concomitant treatment with xanthine derivatives may potentiate any hypokalemic effect of formoterol, a component of DULERA.

7.4 Diuretics
Concomitant treatment with diuretics may potentiate the possible hypokalemic effect of adrenergic agonists. The ECG changes and/or hypokalemia may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of DULERA with non-potassium sparing diuretics.

7.5 Monamine oxidase inhibitors, triyclic antidepressants, and drugs known to prolong the QTc interval
DULERA should be administered with caution to patients being treated with non-selective monoamine oxidase inhibitors, triyclic antidepressants, or drugs known to prolong the QTc interval or within 2 weeks of discontinuation of such agents, because the action of formoterol, a component of DULERA, on the cardiovascular system may be potentiated by these agents. Drugs that are known to prolong the QTc interval have an increased risk of ventricular arrhythmias.

7.6 Beta-adrenergic receptor antagonists
Beta-adrenergic receptor antagonists (beta-blockers) and formoterol may inhibit the effect of each other when administered concurrently. Beta-blockers not only block the therapeutic effects of beta-agonists, such as formoterol, a component of DULERA, but may produce severe bronchospasm in patients with asthma. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with asthma. In this setting, cardioselective beta-blockers could be used, although they should be administered with caution.

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
DULERA: Teratogenic Effects: Pregnancy Category C
There are no adequate and well-controlled studies of DULERA, montelukast furoate or formoterol fumarate only in pregnant women. Animal reproduction studies of montelukast furoate and formoterol in mice, rats, and/or rabbits revealed evidence of teratogenicity as well as other developmental toxic effects. Because animal reproduction studies are not always predictive of human response, DULERA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Montelukast Furoate: Teratogenic Effects
When administered to pregnant mice, rats, and rabbits, montelukast furoate increased fetal malformations and decreased fetal growth (measured by lower fetal body weight and/or delayed ossification). Dystocias and related complications were also observed when montelukast furoate was administered to rats late in gestation. However, experience with oral corticosteroids suggests that rodents are more prone to teratogenic effects from corticosteroid exposure than humans.

In a mouse reproduction study, subcutaneous montelukast furoate produced cleft palate at approximately one-third of the maximum recommended daily human dose (MRHD) on a mcg/m2 basis and delayed in ossification at approximately 3 times the MRHD on a mcg/m2 basis.

In a rat reproduction study, montelukast furoate produced umbilical hernia at topical dermal doses approximately 6 times the MRHD on a mcg/m2 basis and delays in ossification at approximately 3 times the MRHD on a mcg/m2 basis.

In another study, rats received subcutaneous doses of montelukast furoate throughout pregnancy or late in gestation. Treated animals had prolonged and difficult labor, fewer live births, lower birth weight, and reduced early pup survival at a dose that was approximately 8 times the MRHD on an area under the curve (AUC) basis. Similar effects were not observed at approximately 4 times MRHD on an AUC basis.

In rabbits, montelukast furoate caused multiple malformations (e.g., flexed front paws, gait dysfunction, umbilical hernia, hydrocephalus) at topical dermal doses approximately 3 times the MRHD on a mcg/m2 basis. In an oral study, montelukast furoate increased resorptions and caused cleft palate and/or head malformations (hydrocephalus and domed head) at a dose less than the MRHD based on AUC; at a dose approximately 2 times the MRHD based on AUC, most litters were aborted or resorbed [see Nonclinical Toxicology (13.2)].

Nonteratogenic Effects:
Hypoadrenalism may occur in infants born to women receiving corticosteroids during pregnancy. Infants born to mothers taking substantial corticosteroid doses during pregnancy should be monitored for signs of hypoadrenalism.

Formoterol Fumarate: Teratogenic Effects
Formoterol fumarate administered throughout organogenesis did not cause malformations in rats or rabbits following oral administration. When given to rats throughout organogenesis, oral doses of approximately 80 times the MRHD on a mcg/m2 basis and above delayed ossification of the fetus, and doses of approximately 2,400 times the MRHD on a mcg/m2 basis and above decreased fetal weight. Formoterol fumarate has been shown to cause stillbirth and neonatal mortality at oral doses of approximately 2,400 times the MRHD on a mcg/m2 basis and above in rats receiving the drug during the late stage of pregnancy. These effects, however, were not produced at a dose of approximately 80 times the MRHD on a mcg/m2 basis.

In another testing laboratory, formoterol was shown to be teratogenic in rats and rabbits. Umbilical hernia, a malformation, was observed in rat fetuses at oral doses approximately 1.2 times and greater than the MRHD on a mcg/m2 basis. Brachygnathia, a skeletal malformation, was observed in rat fetuses at an oral dose approximately 6,100 times the MRHD on a mcg/m2 basis. In another study in rats, no teratogenic effects were seen at inhalation doses up to approximately 500 times the MRHD on a mcg/m2 basis. In rabbit fetuses at oral doses up to approximately 1,200 times the MRHD on a mcg/m2 basis, no teratogenic effects were observed at oral doses up to approximately 3,000 times the MRHD on a mcg/m2 basis.

8.2 Labor and Delivery
There are no adequate and well-controlled human studies that have studied the effects of DULERA during labor and delivery.

Because beta-agonists may potentially interfere with uterine contractility, DULERA should be used during labor only if the potential benefit justifies the potential risk [see Nonclinical Toxicology (13.2)].

8.3 Nursing Mothers
DULERA: It is not known whether DULERA is excreted in human milk.

Because many drugs are excreted in human milk, caution should be exercised when DULERA is administered to a nursing woman.

Since there are no data from well-controlled human studies in the use of DULERA on nursing mothers, based on data for the individual components, a decision should be made whether to discontinue nursing or to discontinue DULERA, taking into account the importance of DULERA to the mother.

Montelukast Furoate: It is not known whether montelukast furoate is excreted in human milk. However, other corticosteroids are excreted in human milk.

Formoterol Fumarate: In human lactation studies, formoterol was excreted in the milk. It is not known whether formoterol is excreted in human milk.

8.4 Pediatric Use
The safety and effectiveness of DULERA have been established in patients 12 years of age and older in 3 clinical trials up to 52 weeks in duration. In the 3 clinical trials, 101 patients aged 12 years of age and older participated with DULERA. Patients in this age-group demonstrated efficacy results similar to those observed in patients 18 years of age and older. There were no obvious differences in the type or frequency of adverse drug reactions reported in this age group compared to patients 18 years of age and older. Similar efficacy and safety results were
observed in an additional 22 patients 12 to 17 years of age who were treated with 
DULERA in another clinical trial. The safety and efficacy of DULERA have not been 
established in children less than 12 years of age.

Controlled clinical studies have shown that inhaled corticosteroids may 
cause a reduction in growth velocity in pediatric patients. In these studies, the 
mean reduction in growth velocity was approximately 1 cm per year (range 0.3 
to 1.4 cm per year) and appears to depend upon dose and duration of exposure. 
This effect was observed in the absence of laboratory evidence of hypothalamic-
pituitary-adrenal (HPA) axis suppression, suggesting that growth velocity is a more 
sensitive indicator of systemic corticosteroid exposure in pediatric patients than
some commonly used tests of HPA axis function. The long-term effects of this 
reduction in growth velocity associated with orally inhaled corticosteroids, including 
the impact on final adult height, are unknown. The potential for "catch up" growth 
following discontinuation of treatment with orally inhaled corticosteroids has not 
been adequately studied.

The growth of children and adolescents receiving orally inhaled 
corticosteroids, including DULERA should be monitored routinely (e.g., via 
stadiometry). If a child or adolescent on any corticosteroid appears to have growth 
suppression, the possibility that he/she is particularly sensitive to this effect should 
be considered. The potential growth effects of prolonged treatment should be 
weighed against clinical benefits obtained and the risks associated with alternative 
therapies. To minimize the systemic effects of orally inhaled corticosteroids, 
including DULERA, each patient should be titrated to his/her lowest effective dose 
[see Dosage and Administration (2.2)].

8.5 Geriatric Use

A total of 77 patients 65 years of age and older (of which 11 were 75 years 
and older) have been treated with DULERA in 3 clinical trials up to 52 weeks in 
duration. Similar efficacy and safety results were observed in an additional 28 
patients 65 years of age and older who were treated with DULERA in another 
clinical trial. No overall differences in safety or effectiveness were observed 
between these patients and younger patients, but greater sensitivity of some older 
individuals cannot be ruled out. As with other products containing beta₂-agonists, 
special caution should be observed when using DULERA in geriatric patients who 
have concomitant cardiovascular disease that could be adversely affected by 
beta₂-agonists. Based on available data for DULERA or its active components, no 
adjustment of dosage of DULERA in geriatric patients is warranted.

8.6 Hepatic Impairment

Concentrations of mometasone furoate appear to increase with severity of 
hepatic impairment [see Clinical Pharmacology (12.3)].

10 OVERDOSE

10.1 Signs and Symptoms

DULERA: DULERA contains both mometasone furoate and formoterol 
fumarate; therefore, the risks associated with overdose for the individual 
components described below apply to DULERA.

Mometasone Furoate: Chronic overdosage may result in signs/symptoms 
of hypercorticism [see Warnings and Precautions (5.7)]. Single oral doses up to 
8000 mcg of mometasone furoate have been studied on human volunteers with 
no adverse reactions reported.

Formoterol Fumarate: The expected signs and symptoms with overdosage 
of formoterol are those of excessive beta-adrenergic stimulation and/or occurrence 
or exaggeration of any of the following signs and symptoms: angina, hypertension 
or hypotension, tachycardia, with rates up to 200 beats/min., arrhythmias, 
nervousness, headache, tremor, seizures, muscle cramps, dry mouth, palpitation, 
nausea, dizziness, fatigue, malaise, hypokalemia, hyperglycemia, and insomnia. 
Metabolic acidosis may also occur. Cardiac arrest and even death may be 
associated with an overdose of formoterol.

The minimum lethal inhalation dose of formoterol fumarate in rats is 
156 mg/kg (approximately 63,000 times the MRHD on a mcg/m² basis). The 
median lethal oral doses in Chinese hamsters, rats, and mice provide even higher 
multiples of the MRHD.

10.2 Treatment

DULERA: Treatment of overdosage consists of discontinuation of DULERA 
together with institution of appropriate symptomatic and/or supportive therapy.
The judicious use of a cardioselective beta-receptor blocker may be considered, 
bearing in mind that such medication can produce bronchospasm. There is insufficient 
evidence to determine if dialysis is beneficial for overdosage of DULERA. Cardiac 
monitoring is recommended in cases of overdosage.

Manufactured by 3M Health Care Ltd., 
Loughborough, United Kingdom.
Manufactured for Schering Corporation, a subsidiary of

MERCK & CO., INC.
Whitehouse Station, NJ 08889 USA.

Copyright © 2010 Schering Corporation, a subsidiary of Merck & Co., Inc.
All rights reserved. U.S. Patent Nos. 5,889,015; 6,057,307; 6,177,323; 6,068,832; 
706,702; and 7,666,705. The trademarks depicted in this piece are owned by
their respective companies.

6/10 32704107T-JBS
The CMS Council held its quarterly policy making meeting on Sept. 15, 2011.

**EXPAND COUNCIL AND ENGAGE NEW MEMBERS**
- The council could double in size under Bylaws changes approved by 93% of voting councilors. The decision gives affiliated medical organizations a strong voice at Society meetings because it removes the majority membership requirement. In addition, all Cook County hospitals will be offered new positions on the CMS Council. Representatives from affiliated organizations and hospitals will be selected based on their desire to serve.

- The CMS trial membership program remains in effect for another year. Those joining CMS through the program have the option of a phased-in membership dues structure. The extension gives CMS more time to demonstrate value and ease the transition towards full dues-paying membership.

**SUPPORT FOR U.S. HOUSE BILL TO SPUR NEW ANTIBIOTIC R&D**
- A CMS resolution urges strong support for HR 2182, “Generating Antibiotic Incentives Now (GAIN) Act,” national legislation aimed at stimulating antibiotic research and development. Adopted by the Council, the resolution requests adoption and action by ISMS and AMA.

**CHANGES TO SAMARITAN ACT BOOST CPR CAMPAIGN**
- Bystanders who give emergency CPR have new legal protection against civil damages under changes to the Good Samaritan Act that CMS and other groups strongly supported. Persons who render first aid must act in good faith, without compensation, and have met certain training standards, although certification is no longer required. Physician volunteers are needed to give “hands-only” CPR demonstrations throughout Cook County. Interested physicians, residents, and students should fill out and return the form on the facing page.

**FALL VETO SESSION**
- Both the Illinois House and Senate passed a measure to extend the sun-setting Medical Practice Act until Dec. 31, 2012. As of press time, the bill was awaiting Governor Quinn’s signature. In related news, ISMS convinced lawmakers to reject a proposal to double the physician relicensure fee and reduce the renewal cycle. To learn more, please see the ISMS Update section on page 26.

**STATE INSURANCE EXCHANGE**
- In August, ISMS testified before a legislative committee implementing the state insurance exchange. The Society made the point that consumers should have a choice of health plans along with data on the different plan options. (State exchanges are required to be up and running by January 2013 to gain federal approval and begin selling insurance in 2014.) ISMS favors the establishment of an exchange through an existing state agency or as a public-private board, and opposes any price negotiation. An assessment on health plans could cover the yearly cost of running the exchange, estimated at $89 million.
Volunteers needed to spread word: “hands-only” CPR saves lives

Many people die needlessly from sudden cardiac arrest. Please consider giving a few hours of your time to train other health care providers and bystanders how to respond with life-saving CPR.

“Hands-only CPR” is as effective as mouth-to-mouth resuscitation, and is a life skill almost anyone can learn to perform in an emergency. It’s as easy as calling 911, or applying the Heimlich maneuver.

Physicians, residents, and medical students—indeed, anyone with a basic life support provider card from the American Heart Association or Red Cross—is encouraged to get involved.

Teaching skills and a commitment to the Project SMILE (Saving More Illinois Lives through Education) format are essential. (Project SMILE was founded by CMS member Vemuri S. Murthy, MD. Dr. Murthy oversees all training and volunteer activities.)

Volunteers will be trained in the Project SMILE format, either privately or in classes taught by coalition instructors. They will be asked to sign an agreement and assume responsibility for choosing the communities and locations for their presentations.

CMS will recognize each volunteer for his or her contributions during a quarterly Council Meeting or the yearly Annual Dinner Meeting.

**Sign Up for Project SMILE:**

To sign up, please fill out the form below and fax to: (312) 670-3646, or email information to rrubio@cmsdocs.org or to the Chicago Medical Society, 515 N. Dearborn St., Chicago, IL 60654.

For more information, call Ruby Bahena at (312) 670-2550, ext. 344.

Name: _____________________________

Contact Info: _______________________

Related experience or certification: _______________________

CMS offers cornucopia of clinical, practice-based lectures

Members enjoyed an expanded array of lectures and workshops this year, both virtual and on-site, as part of CMS’ updated Midwest Clinical Conference Series.

Quarterly conferences addressed concepts in accountable care delivery, value-based payment, choosing an EMR, measuring patients’ satisfaction, and implementing social media policies.

During a full-day EMR conference, CHITREC representatives were on hand to personally answer questions. A CMS dinner program gave participants direct access to reps from both CHITREC and athenahealth. Still other sessions addressed employment law and human resources policies. A parliamentary procedures skills workshop helped organizational leaders brush up on their speaking and debate skills.

On the clinical side, members earned up to seven hours of CME credit attending lectures on the multi-disciplinary approaches to breast care and end-of-life care.

Many participants said they appreciated having ample time to ask questions and to suggest future educational programs.
**IMPLEMENTING HEALTH COURTS?**

**Medical liability reform still on ISMS’ radar**

SINCE THE DISASTROUS ILLINOIS SUPREME Court ruling in February 2010, ISMS has actively sought out alternative paths to medical liability reform.

For example, the Society vigorously supported a measure to reenact other provisions of the 2005 reform law, such as stronger affidavit of merit and expert witness standards, according to President Wayne V. Polek, MD, in comments before the Chicagoland Patient Safety Summit last Sept. 15-16.

Although the bill did not advance in the General Assembly, the proposed legislation also included improvements to the medical disciplinary process and expanded powers for the Medical Disciplinary Board and Division of Insurance.

ISMS has also pursued the implementation of health courts that could dramatically reduce the cost of defending lawsuits as well as the long adjudication and appeals process. In some models, the court would even pay for independent expert witnesses.

Operating outside the regular court system, specially trained health court judges would consult with neutral experts to make decisions. The standard of care would be based on the less strict “avoidability” standard rather than traditional negligence. Patients could still appeal and would not be forced into settlement if they do not agree to the terms, Dr. Polek noted.

Under the health court model, damages would be paid according to a predetermined schedule.

Dr. Polek encouraged physicians to read the Society’s website “white paper” outlining the principles behind health courts which is available at www.isms.org.

Because the state already has two statutorily created special courts, mental health courts and drug courts, establishing a third court category under Illinois law offers a reasonable alternative, Dr. Polek stated.

**Safe harbors**

The safe harbor concept is another relatively new idea in the medical liability reform debate. The idea is based on the theory that complying with clinical guidelines would shield physicians from medical liability claims regardless of the patient’s outcome, Dr. Polek stated.

Only one state has ever attempted to use them, but never found the right legal case to test the concept.

**Evaluating the “Seven Pillars Approach”**

The Society is looking at “The Seven Pillars Approach to Patient Safety” as an option to make health care delivery safer, more effective, and less costly. This novel means of addressing harm to patients was founded by CMS/ISMS member Timothy McDonald, MD, and was extensively reported on in Chicago Medicine.

A practicing anesthesiologist at UIC Medical Center, Dr. McDonald is chief safety and risk officer for health affairs and co-executive director of the university’s Patient Safety Institute for Excellence. He is widely considered a pioneer in the patient safety movement. Dr. McDonald has presented to the ISMS Board and House, and gives presentations to physicians, administrative staff, and risk managers throughout the state.
A lawyer CANNOT buy the distinction of being a Leading Lawyer. This distinction was earned by being among those lawyers who were most often recommended by their peers in statewide surveys. Respondents COULD NOT recommend themselves or lawyers at their law firm. For a complete list of all Leading Lawyers and to view profiles of the lawyers listed on this page, go to www.LeadingLawyers.com.

Leading Chicago Area Employment Law: Management Lawyers

Elizabeth G. Doolin Chittenden Murday & Novotny LLC Chicago 312.281.3604
Jeralyn H. Baran Chuhak & Tecson PC Chicago 312.444.9300
R. Theodore Clark, Jr. Clark Baird Smith LLP Rosemont 847.378.7700
James S. Barber Clausen Miller PC Chicago 312.606.7712
Cheryl Blackwell Bryson Duane Morris LLP Chicago 312.499.6708
Jon Zimring Duane Morris LLP Chicago 312.499.6753
Peter A. Silverman Figliulo & Silverman PC Chicago 312.251.5275
George J. Matkov, Jr. Ford & Harrison LLP Chicago 312.322.0777
James C. Franczek, Jr. Franczek Radelet PC Chicago 312.786.6110
Ronald J. Hein, Jr. Franczek Radelet PC Chicago 312.786.6150
Lisa A. McGarry Franczek Radelet PC Chicago 312.786.6136
David P. Radelet Franczek Radelet PC Chicago 312.786.6190
Andrea R. Waintroob Franczek Radelet PC Chicago 312.786.6170
James J. Zuehl Franczek Radelet PC Chicago 312.786.6155
William N. Krucks Freeborn & Peters LLP Chicago 312.360.6504
David N. Michael Gould & Ratner LLP Chicago 312.236.3003
Paul J. Chermer Hinshaw & Culbertson LLP Chicago 312.704.3220
Michael J. Leech Hinshaw & Culbertson LLP Chicago 312.704.3133
Tom H. Luetkemeyer Hinshaw & Culbertson LLP Chicago 312.704.3056
Thomas Y. Mandler Hinshaw & Culbertson LLP Chicago 312.704.3456
Daniel K. Ryan Hinshaw & Culbertson LLP Chicago 312.704.3248
James P. Daley K&L Gates LLP Chicago 312.807.4224
Robert H. Brown Laner Muchin Dmbrow Becker Levin and Tominberg Ltd Chicago 312.467.9800
Violet M. Clark Laner Muchin Dmbrow Becker Levin and Tominberg Ltd Chicago 312.467.9800
Joseph M. Gagliardo Laner Muchin Dmbrow Becker Levin and Tominberg Ltd Chicago 312.467.9800
Robert S. Letchinger Laner Muchin Dmbrow Becker Levin and Tominberg Ltd Chicago 312.467.9800
Jill P. O'Brien Laner Muchin Dmbrow Becker Levin and Tominberg Ltd Chicago 312.467.9800
Carl S. Tominberg Laner Muchin Dmbrow Becker Levin and Tominberg Ltd Chicago 312.467.9800
Lawrence Jay Weiner Laner Muchin Dmbrow Becker Levin and Tominberg Ltd Chicago 312.467.9800
Joseph H. Yastrow Laner Muchin Dmbrow Becker Levin and Tominberg Ltd Chicago 312.467.9800
Brian W. Bulger Meckler Bulger Tolson Marick & Pearson LLP Chicago 312.474.7990
Erika Dillon Meckler Bulger Tolson Marick & Pearson LLP Chicago 312.474.7972
J. Stuart Garbutt Meckler Bulger Tolson Marick & Pearson LLP Chicago 312.474.7909
Paul R. Barry Meckler Bulger Tolson Marick & Pearson LLP Chicago 312.474.7134
Peter Petrasik Meckler Bulger Tolson Marick & Pearson LLP Chicago 312.474.4451
Joseph E. Tolson Meckler Bulger Tolson Marick & Pearson LLP Chicago 312.474.7880
Anneliese Wermuth Meckler Bulger Tolson Marick & Pearson LLP Chicago 312.474.7876
Timothy A. Wolfe Meckler Bulger Tolson Marick & Pearson LLP Chicago 312.474.7905
Thomas R. Palmer Meltzer Purtill & Stelle LLC Chicago/Schaumburg 847.330.6048
Robert T. Zielinski Miller Canfield Paddock and Stone PLC Chicago 312.460.4216
Sang-yul Lee Polsinelli Shughart PC Chicago 312.873.3631
John A. Klages Quarles & Brady LLP Chicago 312.715.5060
Adrienne C. Mazura Quarles & Brady LLP Chicago 312.715.5213
Jeffrey S. Pielli Quarles & Brady LLP Chicago 312.715.5216
D. Scott Watson Quarles & Brady LLP Chicago 312.715.5149
Max G. Brittain, Jr. Schiff Hardin LLP Chicago 312.258.5544
Ralph A. Morris Schiff Hardin LLP Chicago 312.258.5553
Henry W. Sledz, Jr. Schiff Hardin LLP Chicago 312.258.5525
Patricia Costello Slovak Schiff Hardin LLP Chicago 312.258.5665
Cary E. Donham Shefsky & Froelich Ltd Chicago 312.836.4038
John G. Levi Sidney Austin LLP Chicago 312.853.7701
Mary Aileen O’Callaghan Smith O’Callaghan & White Chicago 312.419.1000
Terry J. Smith Smith O’Callaghan & White Chicago 312.419.1000
Laura A. White Smith O’Callaghan & White Chicago 312.419.1000
Bruce R. Alper Vedder Price PC Chicago 312.609.7890
Lawrence J. Casazza Vedder Price PC Chicago 312.609.7770
J. Kevin Hennessy Vedder Price PC Chicago 312.609.7868
Margo Wolf O’Donnell Vedder Price PC Chicago 312.609.7608
James A. Spizzo Vedder Price PC Chicago 312.609.7705
Thomas C. Koessl Williams Montgomery & John Ltd Chicago 312.899.5757
David M. Holmes Wilson Elser Moskowitz Edelman & Dicker LLP Chicago 312.704.0550

LeadingLawyers Network
Find a better lawyer, faster!
312.644.7000
LeadingLawyers.com
A Division of Law Bulletin Publishing Company—est. 1854
ISMS MEMBERS LIKE YOU KNOW THAT WE are dedicated to saving you money and representing you in Springfield. Often those two goals go hand-in-hand—and the 2011 veto session of the Illinois General Assembly was just such an occasion.

The Illinois Medical Practice Act was scheduled to expire at the end of November. This law governs the practice of medicine in Illinois, setting out criteria for licensure and standards for discipline. In the past it has been set to expire every ten years, but recently the legislature has only been willing to renew it for a year or two at a time, opening up a “Pandora’s box” of opportunities for legislators, regulators, and other interests to try to change how you practice medicine.

During this year’s renewal negotiations, the Illinois Department of Financial and Professional Regulation (IDFPR) tried to double the fee you pay to renew your medical license, from $300 to $600. These licensure fees are designated for IDFPR’s Medical Disciplinary Fund, but in recent years the General Assembly has been in the bad habit of sweeping the Medical Disciplinary Fund into the state’s General Revenue Fund, sapping needed resources from IDFPR. In light of these sweeps, an increase in medical licensure fees would amount to a “tax increase” on Illinois physicians, and ISMS was not going to stand for it.

Through months of negotiations, our legislative advocacy team stood their ground on this issue. When the time came to vote on the bill, the Illinois Senate and House agreed with us, unanimously passing a renewal bill that included no fee increase for Illinois physicians.

This latest extension of the Medical Practice Act only lasts until Dec. 31, 2012, so it is likely that we will have to fight this and other battles again in the near future. In addition, a state in dire fiscal straits, upheaval in our nation’s health care system, allied health professionals seeking ever-greater expansions in their scope of practice, and a host of other issues are likely to present significant challenges to Illinois physicians in 2012 and beyond.

The moral of the story: ISMS’ legislative advocacy is more valuable than ever to Illinois physicians. Don’t forget to spread the word to your colleagues, who may take for granted the hard work that you help support. Thank you for your membership, and for helping ISMS fight for you!
Nora & Tanzillo, LLP

Over Thirty Years of Experience Representing and Defending Physicians and Hospitals in:

- DEA Proceedings
- Summary Suspensions
- Medicare and Medicaid Disputes
- Medical Staff Disciplinary Proceedings
- Contract Dispute Resolution and Litigation
- Illinois Department of Public Aid Proceedings
- Medical Malpractice Actions and Investigations
- Enforcement and Defense of Restrictive Covenants
- Hospital Privileges, HMO and PPO Disputes and Hearings
- Illinois Department of Professional Regulation Hearings/Investigations

**********

For Additional Information and an Initial Consultation
Contact Robert L. Nora at:

Nora & Tanzillo, LLP
10 S. LaSalle Street
Suite 2500
Chicago, Illinois 60603
312.650.7900
rnora@ntllplaw.com
www.noratanzillo.com
CALENDAR OF EVENTS

January 18

CMS Executive Committee Meeting
8:00 a.m.
CMS Building

January 28

Polish-American Medical Society Annual Gala
Ritz Carlton Hotel
Chicago

February 4

ISMS Board of Trustees Meeting
9:00 a.m.
ISMS Headquarters

February 13-15

AMA National Advocacy Conference
Washington, DC

February 15

CMS Executive Committee Meeting
8:00 a.m.
CMS Building

February 15

CMS Board of Trustees Meeting
9:00 a.m.
CMS Building

February 21

CMS Council Meeting
6:00 p.m.
Maggiano’s Banquets
Chicago

2012 OSHA Workshops on
Bloodborne Pathogens & Beyond:
What Healthcare Professionals Need to
Know Before OSHA is at the Door

WHO SHOULD ATTEND? Physicians, Nurses, Physician Assistants, and Office Managers.

LEARNING STRATEGIES: All workshops are taught by specialists in exposure control. The course is designed for clinicians and their staff.

At the conclusion of this activity, participants should be able to:
• Implement a training program for healthcare employees that may be exposed to bloodborne pathogens.
• Identify appropriate personal protective equipment (PPE).
• Develop an emergency response plan.
• Create a written exposure control plan for healthcare workers assigned as first-aid providers.
• Develop a strategy to prevent the spread of pandemic flu within their practice.

Attend the 2-hour training course, update your exposure control plan, and satisfy most of your annual OSHA regulations today!

2-HOUR OSHA WORKSHOP--
DATES & LOCATIONS:
• Saturday, March 24: DoubleTree by Hilton Hotel (Oak Brook) 10 a.m. – 12N
• Wednesday, April 11: Chicago Medical Society Bldg. (Downtown Chicago) 10 a.m. -12N
• Friday, May 11: Advocate Lutheran Gen. Hospital (Park Ridge) 2 p.m. -4 p.m.
• Wednesday, June 6: Advocate Christ Medical Center (Oak Lawn) 2 p.m.- 4 p.m.
• Wednesday, July 18: Chicago Medical Society Bldg. (Downtown Chicago) 10 a.m.-12N
• Wednesday, August 8: (Webinar) 10 a.m. -12N
• Friday, September 7: DoubleTree by Hilton Hotel (Oak Brook) 9:30 a.m. -11:30 a.m.
• Friday, October 5: Advocate Christ Medical Center (Oak Lawn) 10 a.m. -12N
• Friday, November 2: Advocate Lutheran Gen. Hospital (Park Ridge) 2 p.m. -4 p.m.

For location, CME information, directions, fees and online registration visit: www.cmsdocs.org.
Registration Questions? Call: 312-670-2550 x338.
stability matters.

If there is one thing to learn from the recent financial turmoil, knowing who to trust is paramount.

Medical Protective, a proud member of Warren Buffett’s Berkshire Hathaway, has always believed that to provide our healthcare providers the best defense in the nation, our financial stability needs to be rock-solid, stronger than any other company.

Stability even in the worst of times.
Medical Protective is the only medical professional liability insurance company to protect their healthcare providers through all the business and economic cycles of the last 110 years, including the tough economic times of the Great Depression. We are also proud to have provided unmatched defense and stability during all the medial crises.

We have received higher ratings from A.M. Best and S&P than any other carrier in the healthcare liability industry.

Trust Stability. Trust Medical Protective.

Serving Illinois doctors since 1899. Contact us today for your FREE expert guide to Illinois medmal insurance.

- Call: 800-4MEDPRO
- Email: experts@medpro.com
- Visit: www.medpro.com
- Contact your local Medical Protective agent

All products are underwritten by either The Medical Protective Company® or National Fire and Marine Insurance Company®, both Berkshire Hathaway businesses. Product availability varies based upon business and regulatory approval and may be offered on an admitted or non-admitted basis. ©2011 The Medical Protective Company® All Rights Reserved.
Personnel wanted
FAMILY PRACTICE CLINIC ON CHICAGO’S northwest side is looking for primary care physician. Excellent opportunity with eventu- al partnership and takeover of practice and building. Fax resume to (773) 379-9001 or call (773) 287-2200.

REQUIRE BC/BE IM/FP PHYSICIAN, psychologist, and psychiatrist on a part-time basis to earn compensation for evaluations of disabled patients on behalf of the Social Securi- ty Disability Program. The work is rewarding, challenging, and meaningful. No malpractice insurance is required. No follow-up is re- quired. We have offices in Elgin, Skokie, Chicago, and Zion, Illinois, which require staffing from physicians. You can create your own schedule five days per week. Please con- tact us at: kaledoc@aol.com for further information of call (312) 726-5616.

MOBILE DOCTORS SEEKS A FULL-TIME physician for its Chicago office to make house calls to the elderly and disabled. No night/weekend work. We perform the sched- uling, allowing you to focus on seeing patients. Malpractice insurance is provided and all our physicians travel with a certified medical assis- tant. To be considered, please forward your CV to Nick at nick@mobiledoctors.com; or call (312) 848-5319.

SEEKING BC/BE INTERNIST OR FAMILY practitioner to work with a group in Chicagoland. Please call (773) 884-2782 for in- formation.

PRIMARY CARE—MD AT HOME IS LOOKING to hire BE/BC primary care physicians to make house calls on the elderly homebound. Contact Matt Turman at (312) 243-2223 or email: mtur- man@md-athome.com.

GyneCOLOGiST NEEDED PART-TiME OR full-time for pregnancy terminations in the suburban Chicagoland area. Part-time compen- sation is $125,000; full-time compensation is $150,000 per year. Please send CV to admini- strator@networkgci.net or fax (847) 398-4585.

INFERTILITY SPECiALiST Gynecologist needed in the suburban Chicagoland area. Please send CV to administrator@networkgci.net or fax (847) 398-4585.

UroLOGiST OR UROgynecologist specializing in urinary incontinence needed in the suburban Chicagoland area. Please send CV to administrator@networkgci.net or fax (847) 398-4585.

PART-TiME PHYSiCiANS NEEDED. SURgICAL family planning center in the Chicagoland area needs various specialties including anesthesiologist, gynecologist, urologist, internist, and other specialties. Please send CV to ad- minister@networkgci.net or fax (847) 398-4585.

Office/building for sale/rent/lease
BEAUTiFUL, Furnished medical Office sublease in new medical office complex in the Glen in Glenview. Practice among 100 + pri- vate practice physicians. 4-6 half day sessions are available. High speed internet included. 1 year -3 year sublease available. Call Cindy at 847-404-3153

RESPECTABLE INTERNAL MEDiCiNE practice in southwestern suburb for sale with fully furnished office space. Will help with transition. Email: bhatiah2@gmail.com

SPACE FOR RENT. WINNETKA PROFeS- sional Center. Great downtown location. Two available suites can be rented separately or to- gether for up to six operatories. Call (847) 254-0585.

FOR SALE: BUsY PEDIATRiC FAMiLy practice in northwest suburb of Chicago. Three-minute drive to local medical center; 10 minutes to Woodfield Shopping Mall; com- fortable neighborhood to live in. For details call (847) 612-3299 or email: med168@yahoo.com.

PRACTiCE fOR SALe—18 YeAR FAMiLy medicine practice located in central Illinois. Ex- cellent street visibility. Six exam rooms, x-ray, and lab. Average 10 new patients per week; $5,000 PV in 2010; 98% insurance. Three-year average EBITDA $232,196, SDE $427,196. Great community and school system. Motivated sell- er. Call Terry Flanagan (877) 988-0911 or email: terry@practicebrokers.com.

SOUTH LOOP MEDICAL/PROFESSIONAL office space perfect for psychiatrist, social worker, nutritionist. Includes reception and two exam rooms. Rent is $800 per month in- cluding utilities and taxes. Call Mr. Burstein (847) 254-0585.

Business services
PHYSICIANS’ ATTORNey—exPeRiNCeD and affordable physicians’ legal services in- cluding practice purchases; sales and forma- tions; partnership and associate contracts; col- lections; licensing problems; credentialing; es- tate planning and real estate. Initial consulta- tion without charge. Representing practition- ers since 1980. Steven H. Jesser (847) 424-0200; (800) 424-0060; or (847) 212-5620 (mobile); 5250 Old Orchard Road, Suite 300, Skokie, IL 60077- 4462; sj@sjesser.com; www.sjesser.com.
NO SMALL ACHIEVEMENT:
LEARNING THE BUSINESS OF MEDICINE

CHALLENGE: When Dr. Navalgund came out of medical school, he had all the right medical training. But when he decided to open his own practice, he needed something new — an education in the business side of medicine.

SOLUTION: Dr. Navalgund had the Cash Flow Conversation with his PNC Healthcare Business Banker, who put his industry knowledge to work. Together, they tailored a set of solutions to strengthen his cash flow: loans for real estate and equipment along with a line of credit to grow his practice, plus remote deposit to help speed up receivables.

ACHIEVEMENT: DNA Advanced Pain Treatment Center now has four private practices and a growing list of patients. And Dr. Navalgund has a place to turn for all his banking needs, allowing him to focus on what he does best.

WATCH DR. NAVALGUND’S FULL STORY at pnc.com/cfo and see how The PNC Advantage for Healthcare Professionals can help solve your practice’s challenges, too. Or call PNC Healthcare Business Banker John Cercone at 312-338-5288 to start your own Cash Flow Conversation today.

ACCELERATE RECEIVABLES
IMPROVE PAYMENT PRACTICES
INVEST EXCESS CASH
LEVERAGE ONLINE TECHNOLOGY
ENSURE ACCESS TO CREDIT

The person pictured is an actual PNC customer, who agreed to participate in this advertisement. DNA Advanced Pain Treatment Center’s success was due to a number of factors, and PNC is proud of its role in helping the company achieve its goals. All loans are subject to credit approval and may require automatic payment deduction from a PNC Bank Business Checking account. Origination and/or other fees may apply. Equipment financing and leasing products are provided by PNC Equipment Finance, LLC, which is a wholly owned subsidiary of PNC Bank, National Association. PNC is a registered mark of The PNC Financial Services Group, Inc., BBK-5447 ©2011 The PNC Financial Services Group, Inc. All rights reserved, PNC Bank, National Association, Member FDIC.
In an increasingly complex health care environment, UnitedHealthcare is committed to simplifying physicians’ administrative interactions with us, enabling medical providers to practice patient-centered medicine to optimize outcomes. Over the past three years, UnitedHealthcare has invested in operations to streamline the physician administrative experience and facilitate accurate, timely and transparent claims payment. The way forward in a time of change is a path that we take together with our network.